| |
| |
|
| Insider
Information: |
Wierenga Wendall D |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
167,585 |
|
|
Indirect Shares
|
15,373 |
|
|
| Direct
Value |
$7,596,524 |
|
|
|
Indirect Value
|
$1,634 |
|
|
| Total
Shares |
182,958 |
|
|
| Total
Value |
$7,598,158 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 122.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
EVP, Research & Develo... |
2003-10-10 |
5,023 |
2003-09-01 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
Director |
2013-10-01 |
0 |
2003-11-03 |
0 |
Premium* |
|
|
Xenoport Inc |
XNPT |
Director |
2016-07-05 |
0 |
2006-12-15 |
0 |
Premium* |
|
|
Santarus Inc |
SNTS |
EVP, R&D |
2014-01-02 |
0 |
2014-01-02 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
Director |
2014-03-13 |
12,389 |
|
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2014-10-22 |
20,000 |
2017-01-05 |
15,373 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
Director |
2017-12-11 |
0 |
2015-06-23 |
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
Director |
2024-05-15 |
24,327 |
2020-04-28 |
0 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
Director |
2023-06-16 |
105,846 |
2020-04-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XNPT |
Xenoport Inc |
Director |
– • – |
2005-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
24,998 |
|
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2006-11-06 |
4 |
S |
$23.87 |
$119,550 |
D/D |
(5,000) |
19,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2006-11-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,000 |
15,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2006-12-15 |
4 |
S |
$25.02 |
$100,080 |
I/I |
(4,000) |
0 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2007-05-16 |
4 |
S |
$41.15 |
$205,750 |
D/D |
(5,000) |
10,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2007-12-05 |
4 |
S |
$54.50 |
$164,267 |
D/D |
(3,000) |
7,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2008-08-19 |
4 |
S |
$48.50 |
$194,164 |
D/D |
(4,000) |
3,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2013-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
8,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2014-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
13,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2014-05-27 |
4 |
B |
$3.99 |
$39,900 |
D/D |
10,000 |
23,998 |
2.39 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2015-05-11 |
4 |
B |
$5.63 |
$28,169 |
D/D |
5,000 |
28,998 |
2.39 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2015-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
33,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2016-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
38,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2016-07-05 |
4 |
D |
$7.03 |
$274,156 |
D/D |
(38,998) |
0 |
0 |
- |
|
| SNTS |
Santarus Inc |
EVP, R&D |
• – – |
2014-01-02 |
4 |
D |
$32.00 |
$10,048 |
D/D |
(314) |
0 |
0 |
- |
|
| SNTS |
Santarus Inc |
EVP, R&D |
• – – |
2014-01-02 |
4 |
D |
$32.00 |
$150,848 |
D/D |
(4,714) |
0 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2014-10-22 |
4 |
B |
$1.52 |
$30,364 |
D/D |
20,000 |
20,000 |
2.39 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$2,813 |
I/I |
4,850 |
24,850 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-06-30 |
4 |
A |
$0.40 |
$3,000 |
I/I |
7,510 |
32,360 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-09-30 |
4 |
A |
$0.34 |
$3,000 |
I/I |
8,868 |
41,228 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2017-01-05 |
4 |
A |
$0.00 |
$0 |
I/I |
11,250 |
15,373 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2003-11-03 |
4 |
S |
$24.12 |
$530,859 |
D/D |
(21,980) |
0 |
|
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2003-11-03 |
4 |
OE |
$6.13 |
$201,565 |
D/D |
21,980 |
0 |
|
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2003-11-04 |
4 |
S |
$24.12 |
$302,220 |
D/D |
(12,520) |
0 |
|
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2003-11-04 |
4 |
OE |
$5.63 |
$77,654 |
D/D |
12,520 |
0 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
